Drugs / Candida antigen
last change Dec 2025 re-read 2 minutes ago

Candida antigen

also known as Candidal antigen

Vaccine

Developed for
common wart · human papilloma virus infection · anogenital human papillomavirus infection
Investigated by
Allermed Laboratories, Inc. · University of Arkansas · Zagazig University

Trials 2 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00569231 Feb 2007 → Jan 2010 common wart, human papilloma virus infection University of Arkansas Completed No outcome recorded
Phase 21 trial
Phase 2 NCT04399577 Jul 2017 → Mar 2019 common wart Zagazig University Completed No outcome recorded
Also used as a comparator or background therapy in 5 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT07329907 Comparator Dec 2023 → Jun 2024 common wart, human papilloma virus infection Benha University Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT05254561 Comparator Nov 2020 → Jun 2021 Zagazig University Completed No outcome recorded
Phase 31 trial
Phase 3 NCT03853785 Comparator Feb 2020 → Feb 2021 anogenital human papillomavirus infection Assiut University Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT05429151 Comparator Jun → Nov 2022 Sohag University Unknown No outcome recorded
Phase not applicable1 trial
NCT06749665 Comparator Dec 2024 → Oct 2025 overdue common wart Sohag University Not yet recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as candida antigen “Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL.” NCT05429151
7

Candida antigen.” NCT05254561

NCT00569231

NCT06749665

NCT04399577

NCT05429151

NCT07329907

NCT03853785

Known as Candidal antigen “Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by an insulin syringe in the largest wart at the first visit” NCT03853785
Modality Vaccine “therapeutic vaccination” PMID 26980480 Mar 2016
Route Other “Intralesional injection of 0.3ml candida antigen into largest wart” NCT00569231